Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 9, 2007

Q-Med and Medy-Tox Join Forces to Develop Botulinum Toxin Products

  • Q-Med and Medy-Tox entered into an collaboration agreement for botulinum toxin-based biopharmaceuticals. Q-Med will develop and commercialize new generations of these products for both esthetic and therapeutic indications.

    Under the agreement, Q-Med will pay Medy-Tox milestones up to $8 million provided that specific targets are met. Medy-Tox is entitled to royalties on products developed by Q-Med that are based on its active pharmaceutical ingredients.

    Medy-Tox retains the right of first refusal regarding distribution in India, Thailand, Singapore, and South Korea of newly developed botulinum toxin products.

    In return for Medy-Tox’ support, Q-Med will provide an additional conditioned $3 million to help Medy-Tox expand its facilities in Ochang-myeon in South Korea.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »